Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alnylam Pharmaceuticals, Inc.

NASDAQ: ALNY · Life Sciences · 6 alerts · CIK 1178670

Share price
$159.73Close, Nov 16
Market cap
$21.4B
Shares outstanding
133.94MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alnylam Pharmaceuticals, Inc. filings on SEC EDGAR ↗

8:16 AM ET 8-K
Financial Results

Alnylam Pharmaceuticals Financial Results

Alnylam Pharmaceuticals reported Q3 2026 global net product revenues of $1,292 million, representing 52% year-over-year growth. The performance was driven by its TTR franchise, which grew 59% to $1,150 million, and the company reaffirmed its full-year 2026 financial guidance.

Term
Q3 2026

“Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact. As we continue through the final months of the year and plan for 2027, we remain laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis.”

Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.